Doctronic, a New York City-based provider of an AI system legally authorized to practice medicine in the United States, announced it has raised $40 million in Series B funding, bringing its total funding to more than $65 million.
The round was co-led by Abstract and Lightspeed Venture Partners, with participation from Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures. The financing marks the company’s third funding round in less than a year.
The raise follows a period of rapid growth. In under six months since its Series A, Doctronic reported 15x growth to eight-figure annualized revenue and nearly tripled its repeat patient rate. The platform now attracts more than 300,000 weekly users.
A key milestone came in December 2025, when Doctronic became the first AI-native platform to autonomously renew prescriptions under Utah’s AI Learning Lab regulatory sandbox. The system currently supports prescription renewals across 190 medications, with built-in safety protocols and escalation to licensed physicians when needed.
Founded by Dr. Adam Oskowitz and Matt Pavelle, the company operates its own clinical practice licensed across all 50 states. Its platform is HIPAA-compliant and available 24/7, offering free AI consultations as well as paid physician video visits.
Doctronic’s infrastructure integrates patient records, medication history, and drug interaction screening tools, enabling its AI to conduct structured clinical reasoning through a multi-agent system. The company also maintains a first-of-its-kind AI medical malpractice insurance program where its AI operates independently.
The new funding will be used to expand partnerships with hospital systems, academic institutions, digital health platforms, and payers, while also supporting expansion into pediatrics and continued product development. The company is also in discussions with regulators to extend AI-powered prescription services beyond Utah.
KEY QUOTES:
“Doctronic proved what we believed from the start: AI can deliver better healthcare outcomes at scale. The Utah program validated their clinical rigor. The revenue growth validated market demand. What sets them apart is the courage to take responsibility for outcomes, not just provide information. That’s the future of healthcare.”
Ramtin Naimi, Partner at Abstract
“The combination of user traction, revenue momentum, and partnerships with major health systems makes it clear: Doctronic is the breakout leader in AI-powered medicine. They’ve built autonomous AI that integrates safely into real clinical workflows and brings in real patient context, uniquely delivering on the treatment through triage vision at an unmatched scale.”
Faraz Fatemi, Partner at Lightspeed Venture Partners
“This round reflects Doctronic’s category leadership: unmatched consumer scale and a best-in-class AI clinical model. Health systems see us as infrastructure, the digital front door that routes their patients efficiently and keeps care in-network. Payers see us as unlimited primary care at predictable cost. This round lets us push further into academic medical centers, digital health platforms, and payers, while continuing to serve millions of consumers directly.”
Matt Pavelle, Co-Founder of Doctronic
“We’re not just faster and cheaper than traditional care , we’re more thorough. Our AI performs dozens of safety checks per prescription renewal that would take a human physician an hour. The 99.2% treatment alignment rate isn’t theoretical, it’s from real patients in real clinical scenarios. But what I’m most proud of is retention. Since the Series A, monthly repeat physician visits have nearly tripled. Patients aren’t just trying us, they’re coming back.”
Dr. Adam Oskowitz, Co-Founder of Doctronic
